Early Access — free while we kick the tires
EdgarHawk

KENYON LAWRENCE A

Chief Financial Officer

Director Officer
1 filing analyzed · 1 company · Latest 2024-09-30

Never miss a filing from KENYON LAWRENCE A

Watch this insider and we'll alert you the moment they file — at any company.

Companies

Company Buys Sells Direction
Outlook Therapeutics, Inc. OTLK 1 0 Net buying

Activity

September 2024
medium
Buy
5,000 shares
$28,446
Significance 5/10

CFO Kenyon Lawrence A purchases 5,000 shares of OTLK at $5.69, expanding stake 528.5% amid recent -27.4% monthly decline

Kenyon Lawrence A, Chief Financial Officer, executed a $28,446.00 open-market purchase of 5,000 shares on 2024-09-26 at $5.69, increasing his holdings from 946 shares to 5,946 shares—a 528.5% expansion of his prior position. The purchase occurred as the stock traded -27.4% lower over the preceding 30 days and -59.6% below its 52-week high of $13.20. Fundamentals present a mixed signal: the company reported +163.8% annual revenue growth with recent quarterly revenue of $583.8K, yet reported full-year net income was negative despite the latest quarter showing $44.4M net income—a material inconsistency suggesting potential one-time items, accounting adjustments, or prior-year losses offsetting current profitability. The CFO's substantial increase in personal ownership occurs amid both significant price weakness and unresolved questions about the company's underlying profitability trajectory.

Related insiders